JP2016525548A5 - - Google Patents

Info

Publication number

JP2016525548A5

JP2016525548A5 JP2016529872A JP2016529872A JP2016525548A5 JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5 JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5

Authority

JP

Japan

Prior art keywords

combination

desmopressin

combination medicament

hours

administered

Prior art date

2014-07-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 20
• 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 11
• NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 11
• 229960004281 desmopressin Drugs 0.000 claims 11
• 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 3
• 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 3
• 230000036470 plasma concentration Effects 0.000 claims 3
• 230000002686 anti-diuretic effect Effects 0.000 claims 2
• PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 claims 2
• 229960001551 mirabegron Drugs 0.000 claims 2
• 210000002200 mouth mucosa Anatomy 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• XSOXUIXLUNBLJA-RNRVQEDPSA-N (2r)-6-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid Chemical compound C1([C@@H](O)CN[C@@H](CC=2C=C3OC[C@@H](OC3=CC=2)C(O)=O)C)=CC=CC(Cl)=C1 XSOXUIXLUNBLJA-RNRVQEDPSA-N 0.000 claims 1
• ZGGNJJJYUVRADP-ACJLOTCBSA-N 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(Cl)C=CC=1)C1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-ACJLOTCBSA-N 0.000 claims 1
• VMMYRRFPMAGXNP-BTYIYWSLSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC(C)=C(OCC(O)=O)C=C1C VMMYRRFPMAGXNP-BTYIYWSLSA-N 0.000 claims 1
• HUUHHWPSOFUOEV-UHFFFAOYSA-N 3-methyl-4-(5-oxo-3-phenylimidazolidin-1-yl)benzenesulfonamide Chemical compound CC1=CC(S(N)(=O)=O)=CC=C1N1C(=O)CN(C=2C=CC=CC=2)C1 HUUHHWPSOFUOEV-UHFFFAOYSA-N 0.000 claims 1
• IBPCNRNTIRZRJZ-QFIPXVFZSA-N 4-[4-[2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(C=2C=CC(CCNC[C@H](O)C=3C=C(Cl)C=CC=3)=CC=2)=C1 IBPCNRNTIRZRJZ-QFIPXVFZSA-N 0.000 claims 1
• RDJQCOBTKKAQAH-FPOVZHCZSA-N Amibegron Chemical group C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-FPOVZHCZSA-N 0.000 claims 1
• 239000000048 adrenergic agonist Substances 0.000 claims 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
• 229950008231 amibegron Drugs 0.000 claims 1
• FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 claims 1
• 229950003058 fasobegron Drugs 0.000 claims 1
• 210000002850 nasal mucosa Anatomy 0.000 claims 1
• 230000001766 physiological effect Effects 0.000 claims 1
• 229950008844 ritobegron Drugs 0.000 claims 1
• 229940126158 β3 adrenergic receptor agonist Drugs 0.000 claims 1